

51 - References

References

Drug treatment of psychiatric symptoms in the context of other conditions CHAPTER 10 References

1. Chen LY, et al. Epidemiology of atrial fibrillation: a current perspective. *Heart Rhythm* 2007; 4:S1-S6.
2. Tully PJ, et al. Anxiety, depression, and stress as risk factors for atrial fibrillation after cardiac surgery. *Heart Lung* 2011; 40:4-11.
3. National Institute for Health and Care Excellence. Atrial fibrillation: diagnosis and management. NICE guideline [NG196]. 2021 (last accessed August 2024); <https://www.nice.org.uk/guidance/ng196>.
4. Lakshminarayan K, et al. Clinical epidemiology of atrial fibrillation and related cerebrovascular events in the United States. *Neurologist* 2008; 14:143-150.
5. Rodgers M, et al. Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation. *Health Technol Assess* 2008; 12:iii-iv, xi-xiii, 1-198.
6. Latchamsetty R, et al. Catheter ablation of atrial fibrillation. *Cardiol Clin* 2014; 32:551-561.
7. Saglietto A, et al. Impact of atrial fibrillation catheter ablation on mortality, stroke, and heart failure hospitalizations: a meta-analysis. *J Cardiovasc Electrophysiol* 2020; 31:1040-1047.
8. Hagengaard L, et al. Incident atrial fibrillation and risk of psychoactive drug redemptions and psychiatric hospital contacts: a Danish Nationwide Register-based Follow-up Study. *Eur Heart J Qual Care Clin Outcomes* 2021; 7:76-82.
9. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. *N Engl J Med* 1992; 327:227-233.
10. Epstein AE, et al. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). *JAMA* 1993; 270:2451-2455.
11. Zhang N, et al. Prolonged corrected QT interval in predicting atrial fibrillation: a systematic review and meta-analysis. *Pacing Clin Electrophysiol* 2018; 41:321-327.
12. Emul M, et al. P wave and QT changes among inpatients with schizophrenia after parenteral ziprasidone administration. *Pharmacol Res* 2009; 60:369-372.
13. Chou RH, et al. Antipsychotic treatment is associated with risk of atrial fibrillation: a nationwide nested case-control study. *Int J Cardiol* 2017; 227:134-140.
14. Chen CM, et al. Major bleeding risk in atrial fibrillation patients co-medicated with non-vitamin K oral anticoagulants and antipsychotics. *Front Pharmacol* 2022; 13:819878.

15. Cam B, et al. [Clozapine and olanzapine associated atrial fibrillation: a case report]. *Turk Psikiyatri Dergisi* 2015; 26:221-226.
 16. Low Jr, RA, et al. Clozapine induced atrial fibrillation. *J Clin Psychopharmacol* 1998; 18:170.
 17. Waters BM, et al. Olanzapine-associated new-onset atrial fibrillation. *J Clin Psychopharmacol* 2008; 28:354-355.
 18. Yaylaci S, et al. Atrial fibrillation due to olanzapine overdose. *Clin Toxicol (Phila)* 2011; 49:440.
- Condition Suggested drugs
 Drugs to avoid
 Anxiety disorders (anxiety symptoms increase risk of AF)
 45 Benzodiazepines (although a 2022 cohort study found a hugely increased risk of incident AF in benzodiazepine users)
 46 SSRIs (see above)
 Tricyclics (see above)
 Several reported cases of pregabalin- and gabapentin-associated AF
 47,48 and one cohort study suggested increased risk of AF
 49 with both drugs
 Promethazine may increase the risk of being hospitalised with AF
 50
 Alzheimer's disease
 Acetylcholinesterase inhibitors (but beware bradycardic effects in patients with paroxysmal 'vagal' AF [paroxysmal AF provoked by low heart rate])
 Rivastigmine has least interaction potential
 Memantine may be able to prevent and terminate AF
 51
 Avoid cholinesterase inhibitors in paroxysmal 'vagal' AF
 AV, atrioventricular; DOACs, direct-acting oral anticoagulants.
- Table 10.15 (Continued)

848 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 10

19. D'Urso G, et al. Aripiprazole-induced atrial fibrillation in a patient with concomitant risk factors. *Exp Clin Psychopharmacol* 2018; 26:509-513.
20. Stefatos A, et al. Atrial fibrillation and injected aripiprazole: a case report. *Innov Clin Neurosci* 2018; 15:43-45.
21. Schneider RA, et al. Apparent seizure and atrial fibrillation associated with paliperidone. *Am J Health Syst Pharm* 2008; 65:2122-2125.
22. Zeng J, et al. Metabolic disorder caused by antipsychotic treatment may facilitate the development of atrial fibrillation. *Int J Cardiol* 2017; 239:14.
23. Polcwiartek C, et al. Electrocardiogram characteristics and their association with psychotropic drugs among patients with schizophrenia. *Schizophr Bull* 2020; 46:354-362.
24. Davutoglu V, et al. Valproic acid as a cause of transient atrio-ventricular conduction block episodes. *J Atr Fibrillation* 2017; 9:1520.
25. Kalcik MDM, et al. Acute atrial fibrillation as an unusual form of cardiotoxicity in chronic lithium overdose. *J Atr Fibrillation* 2014; 6:1009.
26. Acharya S, et al. Lithium-induced cardiotoxicity: a rare clinical entity. *Cureus* 2020; 12:e7286.
27. Lange HW, et al. Depressive symptoms predict recurrence of atrial fibrillation after cardioversion. *J Psychosom Res* 2007; 63:509-513.
28. Patel D, et al. A systematic review of depression and anxiety in patients with atrial fibrillation: the mind--heart link. *Cardiovasc Psychiatry Neurol* 2013; 2013:159850.
29. Quinn GR, et al. Effect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin. *Am J Cardiol* 2014; 114:583-586.
30. Komen JJ, et al. Concomitant anticoagulant and antidepressant therapy in atrial fibrillation patients and risk of stroke and bleeding. *Clin Pharmacol Ther* 2020; 107:287-294.
31. Pousti A, et al. Effect of sertraline on ouabain-induced arrhythmia in isolated guinea-pig atria. *Depress Anxiety* 2009; 26:E106-E110.
32. Pousti A, et al. Effect of citalopram on ouabain-induced arrhythmia in isolated guinea-pig atria. *Hum Psychopharmacol* 2003; 18:121-124.
33. Shirayama T, et al. Usefulness of paroxetine in depressed men with paroxysmal atrial fibrillation. *Am J Cardiol* 2006; 97:1749-1751.
34. Emul M, et al. The influences of depression and venlafaxine use at therapeutic doses on atrial conduction. *J Psychopharmacol* 2009; 23:163-167.
35. Finch SJ, et al. Cardioversion of persistent atrial arrhythmia after treatment with venlafaxine in successful management of major depression and posttraumatic stress disorder. *Psychosomatics* 2006; 47:533-536.
36. Shao IY, et al. Association of type of antidepressant initiation with bleeding risk in atrial fibrillation patients taking oral anticoagulants. *Drugs Real World Outcomes* 2021;

8:383–391. 37. Chang KH, et al. Major bleeding risk in patients with non-valvular atrial fibrillation concurrently taking direct oral anticoagulants and antidepressants. *Front Aging Neurosci* 2022; 14:791285. 38. Andrade C. Antidepressants and atrial fibrillation: the importance of resourceful statistical approaches to address confounding by indication. *J Clin Psychiatry* 2019; 80:19f12729. 39. Fenger-Grøn M, et al. Depression, antidepressants, and the risk of non-valvular atrial fibrillation: a nationwide Danish matched cohort study. *Eur J Prevent Cardiol* 2019; 26:187–195. 40. Taylor D. Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety. *Acta Psychiatr Scand* 2008; 118:434–442. 41. Moorehead CN, et al. Imipramine-induced auricular fibrillation. *Am J Psychiatry* 1965; 122:216–217. 42. Rosen BH. Case report of auricular fibrillation following the use of imipramine (Tofranil). *J Mt Sinai Hosp NY* 1960; 27:609–611. 43. Lapi F, et al. The use of antidepressants and the risk of chronic atrial fibrillation. *J Clin Pharmacol* 2015; 55:423–430. 44. Fu Y, et al. Association of depression, antidepressants with atrial fibrillation risk: a systemic review and meta-analysis. *Front Cardiovasc Med* 2022; 9:897622. 45. Eaker ED, et al. Tension and anxiety and the prediction of the 10-year incidence of coronary heart disease, atrial fibrillation, and total mortality: the Framingham Offspring Study. *Psychosom Med* 2005; 67:692–696. 46. Hu X, et al. Hypnotics use is associated with elevated incident atrial fibrillation: a propensity-score matched analysis of cohort study. *J Pers Med* 2022; 12:1645. 47. Chilkoti G, et al. Could pregabalin premedication predispose to perioperative atrial fibrillation in patients with sepsis? *Saudi J Anaesth* 2014; 8 Suppl 1:S115–S116. 48. Park SH, et al. Atrial fibrillation induced by gabapentin: a case report. *J Med Case Rep* 2023; 17:236. 49. Ortiz de Landaluce L, et al. Gabapentin and pregabalin and risk of atrial fibrillation in the elderly: a population-based cohort study in an electronic prescription database. *Drug Saf* 2018; 41:1325–1331. 50. Sessa M, et al. The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine. *Expert Opin Drug Saf* 2020; 19:349–357. 51. Xie D, et al. Memantine targets glutamate receptors in atrial cardiomyocytes to prevent and treat atrial fibrillation. *Cell Discov* 2022; 8:76.

Revision #1

Created 2026-01-04 20:17:54 UTC by Omar Ayman

Updated 2026-01-04 20:17:54 UTC by Omar Ayman